Eli Lilly's obesity drug succeeds in two late-stage studies

FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo

(Reuters) -Eli Lilly said on Thursday its experimental obesity drug met the main goals in two late-stage studies, with the drug helping patients reduce 26.6% weight on average in one of the studies following intensive lifestyle changes.

The company said both the late-stage studies also achieved all secondary goals.